Yin Ning, Xia Jiangyan, Cao Yi-Zhi, Lu Xinjian, Yuan Jing, Xie Jue
Department of Anesthesiology, Sir Run Run Hospital, Nanjing Medical University, Nanjing, Jiangsu, China.
Department of Anesthesiology, Zhongda Hospital, School of Medicine, Southeast University, Nanjing, China.
BMJ Open. 2017 Sep 1;7(9):e014881. doi: 10.1136/bmjopen-2016-014881.
The best methods for inducing analgesia and sedation for gastroscopy are still debated but finding an adequate regimen of sedation/analgesia is important. Stimulation of the larynx under sedation can cause reflex responses. Propofol with opioids has been recommended for gastroscopy sedation but the effects on cough reflex suppression remain unclear. This trial will evaluate the effects of propofol combined with small doses of dezocine, oxycodone, sufentanil or fentanyl for gastroscopy. We hypothesise that better performance may be obtained with a combination of propofol and oxycodone. We will observe the incidence and degree of reflex coughing and gagging under sedation when using propofol combined with one of the above drugs or propofol alone.
This will be a prospective, randomised, double-blind, controlled trial. ASA I-II level patients aged 18-65 years and scheduled for gastroscopy will be included. It is planned that 500 subjects will be randomised to intravenously receive 2-2.2 mg/kg propofol plus 0.5-0.8 μg/kg fentanyl (fentanyl group), 2-2.2 mg/kg propofol plus 0.05-0.08 μg/kg sufentanil (sufentanil group), 2-2.2 mg/kg propofol plus 0.04-0.05 mg/kg dezocine (dezocine group), 2-2.2 mg/kg propofol plus 0.04-0.05 mg/kg oxycodone (oxycodone group), or 2.4-3 mg/kg propofol plus 2-2.5 mL saline (control group) for sedation. The primary endpoint is the incidence and degree of reflex coughing and gagging. The secondary endpoints include the occurrence of discomfort or side effects, the use of jaw thrust, assisted ventilation or additional propofol, recovery time, duration of procedure and Steward score.
This study has been approved by the Institutional Ethics Committee for Clinical Research of Zhongda Hospital, Affiliated to Southeast University (No. 2015ZDSYLL033.0). The results of the trial will be published in an international peer-reviewed journal.
This study has been registered with the Chinese Clinical Trial Register (No. ChiCTR-ICR-15006952).
At the time of manuscript submission, the study was in the recruitment phase.
目前对于胃镜检查诱导镇痛和镇静的最佳方法仍存在争议,但找到合适的镇静/镇痛方案很重要。镇静状态下刺激喉部可引发反射反应。丙泊酚联合阿片类药物已被推荐用于胃镜检查镇静,但对咳嗽反射抑制的影响尚不清楚。本试验将评估丙泊酚联合小剂量地佐辛、羟考酮、舒芬太尼或芬太尼用于胃镜检查的效果。我们假设丙泊酚与羟考酮联合使用可能会有更好的效果。我们将观察丙泊酚与上述药物之一联合使用或单独使用丙泊酚时,镇静状态下反射性咳嗽和恶心的发生率及程度。
这将是一项前瞻性、随机、双盲、对照试验。纳入年龄在18 - 65岁、ASA I-II级且计划进行胃镜检查的患者。计划将500名受试者随机分为静脉注射组,分别接受2 - 2.2mg/kg丙泊酚加0.5 - 0.8μg/kg芬太尼(芬太尼组)、2 - 2.2mg/kg丙泊酚加0.05 - 0.08μg/kg舒芬太尼(舒芬太尼组)、2 - 2.2mg/kg丙泊酚加0.04 - 0.05mg/kg地佐辛(地佐辛组)、2 - 2.2mg/kg丙泊酚加0.04 - 0.05mg/kg羟考酮(羟考酮组),或2.4 - 3mg/kg丙泊酚加2 - 2.5mL生理盐水(对照组)进行镇静处理。主要终点是反射性咳嗽和恶心的发生率及程度。次要终点包括不适或副作用的发生情况、下颌前推的使用情况、辅助通气或额外丙泊酚用量、恢复时间、操作持续时间及Steward评分。
本研究已获得东南大学附属中大医院临床研究机构伦理委员会批准(编号:2015ZDSYLL033.0)。试验结果将发表在国际同行评审期刊上。
本研究已在中国临床试验注册中心注册(编号:ChiCTR - ICR - 15006952)。
在提交稿件时,该研究处于招募阶段。